Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Vitiligo Treatment

Teva and Royalty Pharma announced an agreement intended to accelerate development of Teva's anti‑IL‑15 antibody (TEV‑'408) for vitiligo. The press release includes forward‑looking statements and notes risks related to development, funding and execution.

Teva and Royalty Pharma have announced an agreement aimed at accelerating development of a potential treatment for vitiligo. The program centers on Teva's anti‑IL‑15 antibody candidate, TEV‑'408. The companies' public release frames the arrangement as supportive of development while noting uncertainties. Both Teva and Royalty Pharma include formal forward‑looking statements in the release. Key details: - The agreement is described as intended to accelerate development of TEV‑'408 for vitiligo. - Teva's release highlights that TEV‑'408 development also relates to research in celiac disease and notes several risks that could affect outcomes. - Teva identifies risks including the ability to develop the antibody, to execute the funding agreement with Royalty Pharma, and to advance its broader business strategy and pipeline. - Royalty Pharma's notice reiterates that statements are forward‑looking, may be based on current assumptions, and are not guarantees of future performance. - Both companies state that forward‑looking statements are subject to change and that the information may not be updated beyond the release. Summary: The companies describe the agreement as a step to accelerate development of a potential vitiligo therapy while emphasizing uncertainty and known risks. Undetermined at this time.